295 results
424B5
LCTX
Lineage Cell Therapeutics Inc
14 May 24
Prospectus supplement for primary offering
4:36pm
) restore or augment the patient’s functional activity.
Our business strategy is to efficiently leverage our technology platform and our development … . This reflects a portion of our corporate strategy to capitalize on our process development capabilities by combining them with cell engineering
424B5
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Prospectus supplement for primary offering
4:32pm
the patient’s functional activity.
Our business strategy is to efficiently leverage our technology platform and our development, formulation … growth strategy and adversely affect the market price of our common shares.
You may experience immediate and substantial dilution.
The offering price
424B5
akbd9flhd3
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
j8dmpb 7gbd
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
m34n8yj
10 Nov 22
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:11pm